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Patients with large tracheal lesions unsuitable for conventional endoscopic or open operations may
require a tracheal replacement but there is no present consensus of how this may be achieved. Tissue
engineering using decellularized or synthetic tracheal scaffolds offers a new avenue for airway recon-
struction. Decellularized human donor tracheal scaffolds have been applied in compassionate-use clin-
ical cases but naturally derived extracellular matrix (ECM) scaffolds demand lengthy preparation times.
Here, we compare a clinically applied detergent-enzymatic method (DEM) with an accelerated vacuum-
assisted decellularization (VAD) protocol. We examined the histological appearance, DNA content and
extracellular matrix composition of human donor tracheae decellularized using these techniques.
Further, we performed scanning electron microscopy (SEM) and biomechanical testing to analyze
decellularization performance. To assess the biocompatibility of scaffolds generated using VAD, we
seeded scaffolds with primary human airway epithelial cells in vitro and performed in vivo chick
chorioallantoic membrane (CAM) and subcutaneous implantation assays. Both DEM and VAD protocols
produced well-decellularized tracheal scaffolds with no adverse mechanical effects and scaffolds
retained the capacity for in vitro and in vivo cellular integration. We conclude that the substantial
reduction in time required to produce scaffolds using VAD compared to DEM (approximately 9 days vs. 3
e8 weeks) does not compromise the quality of human tracheal scaffold generated. These ﬁndings might
inform clinical decellularization techniques as VAD offers accelerated scaffold production and reduces
the associated costs.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tracheal tissue engineering has been at the forefront of efforts to
generate bioengineered organs because of the lack of therapeutic
options available for patients with severe tracheal disease [1e5].
Both decellularized and synthetic scaffolds have been transplantedCentre, University College London,
Medicine Section, UCL Institute of
i), s.janes@ucl.ac.uk (S.M. Janes).
Ltd. This is an open access articlein compassionate-use cases [6e10] and subsequent work has
turned to improving the functionality of these transplants. Tech-
niques to improve the quality of cells for transplantation, either
through adult stem cell isolation and expansion [11] or induced
pluripotent stem (iPS) cell technology [12e16], are being investi-
gated but the scaffolds onto which cells are seeded also need to be5 University Street, London, WC1E 6JF, UK.
Child Health and Great Ormond Street Hospital, 30 Guilford Street, London, WC1N
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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for tracheal bioengineering purposes with decellularized [6,8],
synthetic [17] and hybrid stent-based [18] scaffolds at various
stages of development.
Clearly, a scaffold that closely mimics normal airway physiology
in terms of structure and function is highly desirable [19]. For this
reason, decellularization of donor organs is an attractive approach
in tracheal bioengineering because the full complexity of human
tracheal architecture, extracellular matrix (ECM) and regional
structural variation are not yet mimicked by synthetic scaffolds
[20]. Ideally, these properties should be retained whilst simulta-
neously removing all donor cells from the trachea to avoid com-
plications involving immune reaction and rejection after
transplantation [21,22]. Achieving this delicate balance between
cell removal and ECM ultrastructure disruption causes decellula-
rization protocols to take longer than may be ideal for the clinicalFig. 1. Schematic comparison of the human tracheal decellularization techniques comp
method (DEM; left) with a vacuum-assisted decellularization (VAD; right) protocol designed
clinical-grade scaffold production. (B) Outline of protocols applied to tracheal segments. (Cneeds of some tracheal stenosis patients. Clinically applied pro-
tocols have required many weeks for decellularization [8,10,23], a
timeframe that rules out the use of a decellularized scaffold in more
urgent clinical scenarios such as tracheal agenesis or atresia where
the entire trachea is absent and full replacement is required soon
after birth [24,25].
Methods to accelerate the decellularization process are being
developed [26] but as yet no direct comparison of the scaffolds
produced by different methods has been performed using human
tracheae, particularly in terms of their in vivo responses [27]. We
developed an accelerated vacuum-assisted decellularization (VAD)
protocol, which reduces the time required for decellularization
from several weeks [8,10,28] to just nine days (Fig. 1). We hy-
pothesized that VAD would effectively decellularize human
tracheal scaffolds and that the resulting scaffolds would retain
similar biomechanical properties and key extracellular matrixared in this study. (A) This study compares the clinically applied detergent-enzymatic
to reduce the time taken to produce scaffolds and to reduce the costs associated with
) Macroscopic appearance of tracheal scaffolds following decellularization.
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detergent-enzymaticmethod (DEM). Further, we hypothesized that
both VAD and DEM scaffolds would support the engraftment of
primary human airway epithelial cells in vitro and would vascu-
larize to similar extents following in vivo implantation.
2. Materials and methods
2.1. Decellularization of human tracheae
2.1.1. Tissue procurement
Human tracheae were obtained from cadaveric donors (30e80
years age) identiﬁed through the National Health Service Blood and
Transplant (NHSBT) tissue retrieval team, by agreement and with
appropriate consent, following the current clinical practice for non-
living tissue retrieval in the U.K. Ethical approval was obtained
through the National Research Ethics Committee (REC reference 11/
LO/1522). Tracheae were retrieved less than 48 h post mortem and
were removed in their entirety from cricoid to carina. Donor
tracheae were immediately rinsed in 1 L 0.9% normal saline and
surrounding tissue was dissected away. The tracheae were
immersed in 20% chlorhexidine solution for 5 min followed by a
further three rinses in 0.9% saline. Intact tracheae were divided into
two equal halves and these matched donor pairs were processed
for either the clinically applied standard protocol [23] of repeated
cycles of detergent and enzyme (detergent-enzymatic method;
DEM) or frozen and then decellularized using the vacuum-assisted
decellularization (VAD) protocol [26] such that decellularization
using both procotols ﬁnished simultaneously. A matched donor
design was chosen due to the difﬁculties in obtaining large
numbers of human donor organs for research purposes and to
minimize the effect of inter-individual variability on results.
2.1.2. Detergent-enzymatic method (DEM) decellularization
Tracheae were subjected to 25 cycles of distilled water for 72 h
at 4 C, 4% sodium deoxycholate (Sigma) for 4 h and 2000 kU DNase
I in 1 M sodium chloride (Sigma) for 3 h. Tracheae were continu-
ously rotated on a roller throughout the decellularization process
and were stored at 4 C in PBS until use.
2.1.3. Vacuum-assisted decellularization (VAD)
Tracheae to be processed by VAD were aspirated dry and frozen
at 80 C. Tissue was thawed to room temperature for 24 h and
rinsed in PBS. Decellularization was performed in an autoclaved
stainless steel Ricordi chamber. Luer locks with 3-way ports and a
pressure gauge were attached to the chamber such that a vacuum
(1 Torr) could be generated. All decellularization steps were per-
formed under vacuum on a tissue agitator at 140 rpm at 37 C
unless otherwise indicated. All solutions were supplemented with
1% penicillin/streptomycin (Sigma). Tracheae were incubated in
detergent solution containing 0.25% sodium deoxycholate (Sigma)
and 0.25% Triton X-100 (Sigma) in HBBS for 24 h at 37 C. Tracheae
were then rinsed twice in sterile water for 2 h and incubated for a
further 44 h in sterile water at 4 C on a tissue agitator at 20 rpm.
Following the wash step, tracheae were incubated in DNase I (2 kU/
ml) and RNase (4 U/ml) at 37 C for 24 h, followed by another 24 h
wash step in sterile water at 4 C as described above. The DNase/
RNase step andwashwas repeated once prior to a ﬁnal wash step of
sterile water for 48 h at 4 C as described above. Tracheaewere then
stored at 4 C in PBS until use.
2.2. Scaffold characterization
2.2.1. Immunohistochemistry and immunoﬂuorescence
Samples were ﬁxed in 4% paraformaldehyde (PFA) overnightprior to standard processing for parafﬁn embedding. Serial parafﬁn
sections were cut at 5 mm thickness. Haematoxylin and eosin, Pe-
riodic acid-Schiff, picrosirius red and Masson’s trichrome staining
were performed on sections using an automated staining system
(Tissue-Tek). For immunoﬂuorescence staining, slides were dew-
axed using an automated protocol and antigen retrieval was per-
formed using citrate buffer (pH 6.0). Primary antibodies against
cytokeratin 5 (CK5; Abcam; ab17130), collagen IV (COL-94; Abcam;
ab6311) and laminin (Sigma; L9393) were used. Species-
appropriate secondary antibodies conjugated to AlexaFluor dyes
(Molecular Probes) were then used. Images were acquired using a
Zeiss LSM700 confocal microscope. For immunohistochemistry,
slides were dewaxed and antigen retrieved as for immunoﬂuores-
cence. Primary antibodies against CD45 (Abcam; ab10558), endo-
mucin (V.7C7.1; Abcam; ab106100) and F4/80 (Serotec;
MCA497GA) were used. Sections were then incubatedwith species-
appropriate biotinylated F(ab’)2 for 30 min, developed using ABC
reagent and superDAB (Dako) and ﬁnally counterstained with
haematoxylin.
2.2.2. Whole-mount immunocytochemistry
For whole-mount imaging, cell-seeded scaffolds were ﬁxed in
4% PFA for 30 min and blocked for 1 h in blocking buffer (10% fetal
bovine serum in PBS containing 0.01% Triton X-100). CK5 primary
antibody (Abcam; ab17130) incubation was overnight at 4 C in
blocking buffer without Triton X-100. Scaffolds were washed three
times in PBS for 5 min and species-appropriate secondary antibody
(AlexaFluor dyes; Molecular Probes) was added for 2 h at room
temperature. Scaffolds were washed three times in PBS and DAPI
(1:10,000 in PBS) was applied to counterstain scaffolds before im-
aging. Scaffolds were oriented luminal-side down on a low-proﬁle
chamber-well slide (Ibidi; #80826) for image acquisition using a
LSM700 confocal microscope (Zeiss).
2.2.3. DNA quantiﬁcation
Isolation of DNA from tracheal samples was performed using a
PureLink DNA extraction kit (Invitrogen) according to the manu-
facturer’s instructions. Brieﬂy, samples were digested overnight in
proteinase K and DNA was isolated using the supplied buffers and
mini-columns. Quantiﬁcation of eluted DNA was carried out by
spectrophotometry using a NanoDrop 8000 (Thermo Scientiﬁc). All
samples had a 260/280 ratio of between 1.8 and 2.0.
2.2.4. Extracellular matrix quantiﬁcation
Collagen, elastin and glycosoaminglycans were quantiﬁed as
previously described [29]. Collagen contentwas determined using a
total collagen assay kit (QuickZyme Biosciences) according to the
manufacturer’s instructions. Representative whole tracheal sam-
ples of native and decellularized tracheawereweighed and directly
hydrolyzed in 6 M HCl for 20 h at 95 C. Samples were allowed to
cool to room temperature and centrifuged to remove debris. To
detect hydroxyproline residues, supernatants were mixed with a
chromogen solution for 1 h at 60 C. Absorbance for each sample
was read using a colorimetric reader (555 nm). Standards were
generated by serial dilution of rat tail collagen I (BD Biosciences)
from 300 mg/ml.
Elastin quantiﬁcation was performed using an elastin assay kit
(FASTIN, Biocolor). Representative whole tracheal samples of both
native and decellularized tissue were homogenized and solubilized
twice with 0.25 M oxalic acid incubated at 95 C. Extracts were
combined with FASTIN dye reagent (5,10,15,20-tetraphenyl-
21H,23H-porphine tetrasulfonate (TPPS)) and the absorbance was
determined at 555 nm. Concentrations were determined using a-
laminin standards.
The sulphated glycosaminoglycan (sGAG) content was
C.R. Butler et al. / Biomaterials 124 (2017) 95e10598quantiﬁed according to the Blyscan GAG Assay Kit (Biocolor).
Representativewet tissue samples were incubated in 1ml of papain
digestion buffer at 65 C for 18 h. Aliquots of each sample were
mixed with 1,9-dimethyl-methylene blue dye and the reagents
from the GAG assay kit. The absorbance was read at 656 nm and
quantiﬁed according to standards generated from bovine tracheal
chondroitin-4-sulphate.
2.2.5. Scanning electron microscopy
Scanning electron microscopy (SEM) images show the luminal
surface of decellularized human donor tracheal scaffolds. Scaffolds
were ﬁxed in 2.5% glutaraldehyde in 0.1 M phosphate buffer,
washed with 0.1 M phosphate buffer (pH 7.4), post ﬁxed with 1%
osmium tetraoxide and 1.5% potassium ferrocyanine in 0.1 M
phosphate buffer and rinsed with distilled water. Specimens were
then dehydrated to 100% ethanol using a graded ethanol-water
series and critical-point dried using carbon dioxide. Samples were
mounted onto aluminum stubs with sticky carbon tabs. A Gatan ion
beam coater was used to coat scaffolds with a layer of Au/Pd
(approx. 2 nm thickness). Images were obtained using a 7401 FEG
scanning electron microscope (Jeol, USA).
2.2.6. Mechanical testing
All decellularized tracheal samples were equilibrated to room
temperature prior to testing and kept hydrated in PBS for me-
chanical testing. Each trachea was cut into 3 cm sections and
compressed with antero-posterior and lateral compressive forces.
The load (N) exerted by the scaffold was calculated when the
scaffold was compressed to 50% of the starting diameter. Further
tracheal samples were cut into dumbbell sections with a template
cutter such that vertical (axial) forces across tracheal rings and
trachealis could be applied. A further dumbbell section was hori-
zontally cut across a tracheal ring. The load required to pull apart
the sample until breaking point was measured using an Instron
5565 tensile tester (Instron Ltd., UK). The tensile stress versus strain
properties were assessed at a displacement rate of 50e100 mm/
min. The Young’s modulus is a measure of material stiffness and
was calculated using Bluehill software (Instron, U.K.) as the slope of
the straight line portion between 0 and 5 mm.
2.3. Epithelial cell seeding and tracking on decellularized scaffolds
2.3.1. Primary epithelial cell seeding
Primary human bronchial epithelial cells (HBECs) were obtained
either by enzymatic digestion from donor human trachea or from
explant biopsy outgrowth [30]. Primary HBECsweremaintained for
up to three passages in bronchial epithelial growth medium
(BEGM; Lonza, UK) as previously described [31]. Decellularized
human tracheal scaffolds were cut into 5 mm discs using a biopsy
punch, such that they ﬁtted into 96-well plate wells. Prior to
epithelial seeding, scaffolds were oriented with luminal/mucosal-
surface side up in a low-adhesion 96-well plate (Nunc) and incu-
bated overnight in 200 ml of BEGM medium. Epithelial cells were
seeded at 0.25 106 cells/cm2, 0.5 106 cells/cm2 or 1.0 106 cells/
cm2 and allowed to adhere overnight. Scaffolds were transferred to
new low-adhesion plates with the same orientation maintained.
Subsequently, medium was changed every 48 h.
2.3.2. Generation of luciferase-tagged immortalized HBECs
Immortalized human bronchial epithelial cells (iHBECs; a gift
from Dr. Gisli Jenkins, University of Nottingham, U.K.) were trans-
duced withmStrawberry-Luc lentivirus to create a stable iHBEC cell
line co-expressing mStrawberry ﬂuorescent protein and luciferase.
Lentivirus production was as previously described [32] but created
with the pLV-LS1 transfer vector and the packaging and envelopevectors pCMV-dR8.74 and pMD.G2 (Plasmid Factory). Brieﬂy, viral
supernatants were created by co-transfecting 293T HEK cells with
the above plasmids using JetPEI (Polyplus Transfection). Superna-
tant containing lentivirus was collected at 48 and 72 h and was
concentrated by ultracentrifugation. Each collection underwent
ultracentrifugation to concentrate virus. To generate a transduced
cell line, iHBECs were grown in LHC9 medium (Gibco), seeded at
1  105 cells in a T25 ﬂask and transduced at an MOI of 7.5 with
4 mg/ml polybrene (Sigma). After 8 h, medium was changed and
cells were passaged when approximately 80% conﬂuent. To obtain a
pure luciferase-expressing population, mStrawberry ﬂuorescent
protein-expressing cells were sorted by ﬂuorescence-activated cell
sorting (FACS) using a BD Aria ﬂow cytometer.
2.3.3. In vitro cell tracking using IVIS imaging
IVIS imaging (Caliper Life Sciences) was used as a non-invasive
in vitro method of tracking luciferase-tagged iHBECs on decellu-
larized human tracheal scaffolds by detecting a luminescence
signal from cells in the presence of the luciferase substrate luciferin.
Scaffolds were fashioned into 5 mm discs and placed into 96-well
plate wells with the luminal surface facing upwards. Scaffolds
were incubated in LHC9 medium (Gibco) overnight at 37 C and 5%
CO2. Cells were seeded on the scaffolds and transferred to a new
low adhesion plate prior to imaging. D-luciferin was added to the
medium at 150 m-g/ml and scaffolds were imaged within the plates
at position ‘C’ using automatic acquisition times.
2.4. In vivo scaffold integration
2.4.1. Chick chorioallantoic membrane (CAM) assay
Fertilized chicken eggs (Henry Stewart and Co., UK) were incu-
bated at 37 C. After 3 days of incubation, an approximately 3 cm
diameter window was cut into the shell using dissecting scissors,
revealing the embryo and CAM vasculature. Windows were sealed
with tape and eggs were returned to the incubator for 5 days. At day
8 of incubation, decellularized human tracheal scaffolds (approxi-
mately 2e3 mm3) and pieces of absorbable gelatin sponge (Gel-
foam; Pﬁzer; a negative control) were placed on the CAM between
blood vessels. Scaffolds were checked daily for 6 days, when scaf-
folds were photographed in ovo with a stereomicroscope (Leica).
Vessel ingrowthwas quantiﬁed blindly as previously described [33].
2.4.2. Xenotransplantation of decellularized human trachea
Human tracheal scaffolds were prepared as described above and
cut into full thickness 5e7mm2 pieces, irradiatedwith 10,000 Gy to
ensure sterility and stored in PBS prior to implantation. Adult CD1
mice were used for subcutaneous implantation of scaffolds. Live
animal work was ethically approved and carried out under Home
Ofﬁce Project Licence PPL 70/7504. Brieﬂy, CD1 mice were anaes-
thetized with a 2e5% isoﬂorane:oxygen gas mix for induction and
maintenance. Under aseptic conditions, the dorsum of the mouse
was shaved and chlorhexidine was applied to the skin. 5 mm
transverse incisions over each dorsal ﬂank were made and subcu-
taneous pockets created. One scaffold was inserted in each pocket
and these were closed with buried 4/0 Vicryl interrupted sutures.
Scaffolds were implanted for 56 days and the experiments were
terminated accordingly. Scaffolds were retrieved en bloc for histo-
pathological analysis.
2.5. Statistical analysis
Results are presented as mean ± standard deviation. Data were
analyzed in Microsoft Excel and GraphPad Prism 6.0. Statistical
tests are indicated in ﬁgure legends and signiﬁcance was accepted
at the 5% level.
Fig. 2. Human donor trachea is efﬁciently decellularized by the accelerated vacuum-assisted decellularization (VAD) protocol. (A) The histological appearance of human
tracheae decellularized using both the clinically applied detergent-enzymatic method (DEM; left) and a vacuum-assisted decellularization protocol (VAD; right) are shown using
haematoxylin and eosin (H&E), periodic acid-Schiff [15], picrosirius red (PSR) and Masson’s trichrome (MT) staining. Scale bars ¼ 500 mm or 50 mm, as indicated. (B) Decellularized
tissue composition was analyzed by comparing DNA, collagen, elastin and sulphated glycosaminoglycan (sGAG) content with native human trachea. Six donor matched tracheae
were assessed and data were analyzed using a Kruskal-Wallis test (ns ¼ non-signiﬁcant, ** ¼ p < 0.01, *** ¼ p < 0.001). (C) Scanning electron microscopy (SEM) images of human
tracheae decellularized using DEM or VAD. Upper panel scale bar ¼ 200 mm; middle panel ¼ 50 mm; lower panel ¼ 5 mm. (D) Immunoﬂuorescence staining of DEM- or VAD-
prepared human trachea using antibodies against laminin (red) and collagen IV [12] and counterstained with DAPI (blue). Scale bar ¼ 50 mm. (For interpretation of the refer-
ences to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.1. VAD decellularizes human tracheae with similar efﬁcacy to the
clinically applied DEM
3.1.1. Histological assessment
To assess the efﬁcacy of vacuum-assisted decellularization
(VAD) we compared this protocol with the clinically applied
detergent-enzymatic method (DEM). Histologically, VAD removed
nuclei from the epithelium, the submucosal glands and the tracheal
cartilage but cartilage lacunae remained intact in both scaffolds
(Fig. 2A). Periodic acid-Schiff (PAS) staining demonstrated theFig. 3. The biomechanical properties of human donor tracheae are retained followin
protocol. (A) Anterior-posterior (AP) compression. (B) Lateral compression. (C) Cartilage rin
and Young’s modulus. (E) Trachealis (vertical/uniaxial) ring stress, strain and Young’s modulu
test (ns ¼ non-signiﬁcant).widespread retention of proteoglycans and glycoproteins in carti-
lage and also in submucosal glands, which may reﬂect the protec-
tion of the glandular basement membrane during decellularization
(Fig. 2A). Picrosirius red (PSR) staining demonstrated the wide-
spread retention of collagen I and III ﬁbers within tracheal scaffolds
decellularized using both DEM and VAD, ﬁndings supported by
Masson’s trichrome (MT) staining (Fig. 2A).3.1.2. Scaffold composition
Reﬂecting the extensive decellularization by both protocols, the
DNA content of scaffolds was signiﬁcantly reduced in comparison
to native trachea (Fig. 2B). While there was a trend towards lowerg decellularization using an accelerated vacuum-assisted decellularization (VAD)
g stress, strain and Young’s modulus. (D) Trachea (vertical/uniaxial) ring stress, strain
s. 4 donor tracheae in at least technical triplicates were analyzed using a Kruskal-Wallis
C.R. Butler et al. / Biomaterials 124 (2017) 95e105 101DNA content in VAD tracheae as compared to DEM tracheae,
consistent with results following the application of vacuum pres-
sure to porcine tracheal decellularization [26], this did not reach
statistical signiﬁcance. However, the abundance of structural
components of scaffolds such as elastin, collagen and sulphated
glycosaminoglycans (sGAGs) was not signiﬁcantly affected by either
DEM or VAD decellularization (Fig. 2B).
3.1.3. Scanning electron microscopy
Scanning electron microscopy (SEM) of decellularized scaffolds
conﬁrmed the absence of cells in both DEM and VAD scaffolds and
showed the folded macroarchitecture characteristic of human tra-
chea. At higher magniﬁcation, a meshwork of ﬁbers was visible on
the luminal surface of both scaffolds (Fig. 2C). However, the base-
ment membrane proteins laminin and collagen IV were not found
at the luminal surface using immunoﬂuorescence but were
retained deeper within scaffolds (Fig. 2D).
3.2. Biomechanical properties of human tracheae are retained
following decellularization
An important aspect of tracheal bioengineering is the structural
integrity of scaffolds post-transplantation. To assess whether VAD
compromises scaffold mechanical properties, we compared theseFig. 4. Primary human airway epithelial cell seeding of decellularized human donor tr
(HBECs) seeded onto either detergent-enzymatic (DEM) or vacuum-assisted decellularizatio
using an antibody against the airway basal cell marker cytokeratin 5 (CK5; green) and cou
images show the morphology of primary HBECs on scaffolds after 72 h. Scale bar ¼ 50 mm (
human bronchial epithelial cells (iHBECs) demonstrates the comparable survival of cells after
of iHBECs seeded at 1  106 cells/cm2 (n ¼ 3 technical triplicates; representative of three in
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred tscaffolds with DEM-decellularized and native tracheae. We found
that decellularization did not signiﬁcantly affect a scaffold’s ability
to resist compression in either the anterior-posterior (Fig. 3A) or
lateral (Fig. 3B) axes. Further, the elastic properties of the cartilage
rings (Fig. 3C), the tracheal wall (Fig. 3D) and the trachealis (Fig. 3E)
were not signiﬁcantly affected by VAD or DEM decellularization.
3.3. Cytocompatibility of decellularized human trachea following
decellularization
3.3.1. Epithelial cell attachment to decellularized scaffolds
For VAD-decellularized tracheae to be of use clinically, the
scaffolds must retain the capacity to support cells in addition to
retaining their mechanical properties. As airway epithelial cells
represent a key functional aspect of bioengineered tracheae
[34,35], we examined the adhesion of primary human bronchial
epithelial cells (HBECs) to the luminal surface of DEM- and VAD-
prepared scaffolds in vitro. By immunoﬂuorescence staining 72 h
post-seeding, we observed that HBECs adhered well to both scaf-
folds but that high seeding densities improved the retention of cells
in both types of scaffold (Fig. 4A). Scanning electron microscopy
(SEM) of scaffolds seeded at 1  106 cells per cm2 also demon-
strated that cells had adhered to both grafts and revealed possible
morphological differences between DEM- and VAD-preparedachea demonstrates cytocompatibility. (A) Primary human bronchial epithelial cells
n (VAD)-decellularized human tracheal scaffolds. Scaffolds were ﬁxed at 72 h, stained
nterstained with DAPI (blue). Scale bars ¼ 100 mm. (B) Scanning electron microscopy
left) and 10 mm (right). (C) Bioluminescence imaging of luciferase-tagged immortalized
72 h on decellularized scaffolds in vitro. (D) Quantiﬁcation of bioluminescence imaging
dependent experiments) over 5 days for both DEM- and VAD-decellularized scaffolds.
o the web version of this article.)
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VAD scaffolds, a possible indication of more mature cellular adhe-
sions to scaffolds in the VAD condition (Fig. 4B).
3.3.2. Cell survival on decellularized scaffolds using luciferase-
tagged epithelial cells
In order to monitor cells in real time on decellularized scaffolds,
we monitored the bioluminescence of luciferase-transduced
immortalized human bronchial epithelial cells (iHBECs) using an
in vivo imaging system (IVIS). Non-invasive monitoring of cells on
the decellularized scaffolds using this system demonstrated a sta-
ble signal over the 5-day period. VAD scaffolds had higher signals
throughout this experiment, apparently caused by higher initial
engraftment of cells on VAD scaffolds compared to DEM scaffolds
(Fig. 4C and D). However, we cannot rule out that differences be-
tween the decellularization protocols, such as enzyme concentra-
tion, affected these results as scaffolds were stored identically after
decellularization and optimization of this stepmay be necessary for
optimal cell seeding.
3.4. In vivo behavior of DEM/VAD-decellularized tracheal scaffolds
3.4.1. Chorioallantoic membrane assays
For cells seeded ex vivo to survive following transplantation,
there is a clear need for rapid integration and angiogenesis inFig. 5. Acellular human tracheal scaffolds are pro-angiogenic in vivo. (A) To assess the ca
decellularized (VAD) human donor tracheal scaffolds were transplanted into a chick chorioa
post implantation are shown. (B) Macroscopic quantiﬁcation of vessels converging on th
membrane served as a negative control. Data were analyzed using a Kruskal-Wallis test (
analyzed in technical triplicate; for controls, n ¼ 6).implanted decellularized scaffolds. To assess the potential of DEM-
and VAD-prepared scaffolds for vascular integration, we performed
chick chorioallantoic membrane (CAM) assays [29,36] using frag-
ments of either DEM- or VAD-decellularized human tracheae.
Gelfoam® acted as a negative control. Macroscopically, we observed
a spoke-wheel pattern of vessels four days after implantation,
which suggested that vessels were attracted to both DEM- and
VAD-prepared scaffolds (Fig. 5A). Quantiﬁcation of the number of
vessels converging on the decellularized scaffolds revealed that
decellularized scaffolds stimulated signiﬁcantly more vessel
ingrowth than negative controls (Fig. 5B) and that the accelerated
VAD protocol did not negatively inﬂuence vessel ingrowth (Fig. 5A).
3.4.2. Xenotransplantation assays
Finally, we compared the behavior of DEM- and VAD-prepared
human tracheal scaffolds in a xenotransplantation assay. 3 mm3
pieces of either DEM- or VAD-prepared tracheae were implanted
subcutaneously into immunocompetent CD1 mice and retrieved
after 8 weeks. Throughout the experiment the mice behaved nor-
mally without evidence of inﬂammation, extrusion of the implan-
ted tissue or death. At the time of retrieval, tissue surrounding the
implants appeared healthy, without signs of adverse reaction.
Histological analyses revealed that DEM- and VAD-prepared
tracheal scaffolds showed similar cellular inﬁltration around the
graft (Fig. 6A) and that this was predominantly macrophagespacity of scaffolds for vascularization, detergent-enzymatic (DEM) or vacuum-assisted
llantoic membrane (CAM) assay. Examples of DEM- and VAD-prepared scaffolds 8 days
e scaffolds was performed for at least six replicates of each scaffold type. Polyester
ns ¼ non-signiﬁcant, *** ¼ p < 0.001; for decellularized scaffolds, three donors were
Fig. 6. Biocompatibility and cellular integration of decellularized human tracheal scaffolds in a subcutaneous transplantation model. Detergent-enzymatic (DEM) or
vacuum-assisted decellularized (VAD) human donor tracheal scaffolds were implanted subcutaneously (n ¼ 4) in CD1 mice and evaluated after 8 weeks. (A) Haematoxylin and eosin
(H&E) staining of representative recovered scaffolds are shown. Scale bars ¼ 500 mm. Immunohistochemical staining was carried out using antibodies against (B) the macrophage
marker F4-80 (scale bars ¼ 250 mm) and (C) the endothelial cell marker endomucin to show neovascularization within the implanted scaffolds (scale bars ¼ 250 mm). (D) Higher
magniﬁcation of the insert shown in (C). Scale bars ¼ 50 mm.
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types as demonstrated by endomucin-stained vessels within the
grafts (Fig. 6C and D).
4. Discussion
We show that a vacuum-assisted decellularization (VAD) pro-
tocol produces human tracheal scaffolds with comparable decel-
lularization efﬁciency, extracellular matrix retention, mechanical
properties, cytocompatibility and in vivo integration capacity to
scaffolds decellularized using the clinically applied detergent-
enzymatic method (DEM). However, VAD is an accelerated proto-
col requiring only 9 days from donor tissue procurement to ﬁnal
decellularized scaffold; by contrast, the DEM method takes 3e8
weeks [8,10,23]. The efﬁcacy of decellularization reported here is in
line with previously published accepted standards for tissue
decellularization [37]. These results are an important step towards
the use of decellularized human cadaveric donor tracheae as scaf-
folds for airway bioengineering because expedited preparation
broadens the clinical scenarios in which decellularization is
appropriate. The incorporation of a freezing step prior to decellu-
larization is of particular importance as it suggests banking of
donor tracheae as a clinically relevant strategy. An important
consideration is that current protocols for storage of pre-
decellularized tracheae mean their salient properties might dete-
riorate over time in storage [38] and the optimization of storage
conditions for decellularized materials is a priority for the ﬁeld.
Production of decellularized scaffolds that share similar
biomechanical properties to native tissue is an important aim as the
tracheal cartilage maintains a patent airway in healthy individuals.
Previous studies suggest that decellularization using some pro-
tocols could negatively affect the structural properties of porcine
tracheae [39]. Here, we comprehensively tested the biomechanical
properties of VAD-decellularized human tracheae including lateral
and antero-posterior compression ﬁnding that the resistance to
compression and elastic properties remain similar to that of native
human tracheae. It is noteworthy that donor tracheae have quite
large variance between samples and this may contribute to non-
signiﬁcant differences found despite controlling for this with
matched samples. In the future, particularly for clinical application,
donor selection criteria may have to be more stringent than they
have been for research purposes.
Scaffold preparation represents the ﬁrst step in the process of
generating a transplantable tissue-engineered airway. Clinically
applied protocols have recellularized scaffolds with autologous
cells, including epithelial cells, mesenchymal stromal cells (MSCs)
and MSC-derived chondrocytes [6,8e10]. As such, it is important
that, as well as maintaining the expected mechanical properties,
scaffolds are able to support the adherence and survival of relevant
cell types. Here, we demonstrated that human bronchial epithelial
cells (HBECs) attach to and survive on both decellularized human
scaffold types in vitro. However, neither the DEM or VAD decellu-
larization method preserved the basement membrane that is nor-
mally present beneath airway epithelial cells; instead, a mesh of
ﬁbers ordinarily constrained to the stromal compartment was
presented at the luminal surface [40]. This may explain the high
seeding densities of HBECs required for cell retention as many cells
may undergo apoptosis before basement membrane production
and/or remodeling occurs. We believe that future studies should
investigate the importance of the basement membrane in airway
bioengineering: basement membrane retention or reconstruction
could improve the cytocompatibility of both decellularized and
synthetic scaffolds, which presently require huge numbers of
HBECs to re-epithelialize [11]. Authors treating severe skin burns
with cultured epidermal stem cells found that the application ofthese cells on a ﬁbrin sheet greatly improved the ‘take rate’ and
ease of application [41]. Similar to other tissue- engineered
epithelia, it may also be possible to transplant airway epithelium as
a pre-prepared sheet product [42,43] or as organoids [44]. Opti-
mization of protocols for functional airway differentiation, to
generate a ciliated epithelium on VAD human scaffolds, as has been
demonstrated in rodent tracheal scaffolds [45], is also desirable.
Pre-seeding and integration of stromal cells into VAD scaffolds
could also be considered [46].
The mechanism, time-course and quality of vascularization of
tissue-engineered constructs is presently unknown and requires
further research, as highlighted at a recent international consensus
meeting [47]. We believe that our data demonstrating comparable
behavior of DEM and VAD scaffolds in terms of their ability to
promote a rapid angiogenic response in CAM experiments and
comparable vascular integration as subcutaneous implants provide
reassurance that reducing the time taken to prepare scaffolds using
a vacuum system does not have detrimental effects on scaffold
performance.
In the trachea, translation of these protocols into clinical prac-
tice will require the development of equipment capable of deliv-
ering vacuum pressure to GMP standards. While the reagents used
in the protocol reported here have previously been adapted to-
wards GMP manufacture, the development of standard operating
procedures and quality control measures for VAD will be an
important step towards this. Further, the concept of VAD might be
useful in clinical protocols to produce decellularized scaffolds from
other organs but protocols will likely require customization to each
setting.
5. Conclusion
This comparison between clinically used DEM decellularization
and accelerated vacuum-assisted decellularization (VAD) of human
tracheae shows that VAD can rapidly generate decellularized
tracheal scaffolds that are comparable to those previously used for
clinical transplantation in a number of key aspects. Importantly,
this innovative procedure allows for banking of tracheae prior to
decellularization for future applications. The similar properties of
DEM and VAD scaffolds both ex vivo and in vivo provide a rationale
for the use of VAD in clinical applications of tissue-engineered
airway scaffolds.
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